Angiogenic activity of osteopontin-derived peptide SVVYGLR

Biochemical and Biophysical Research Communications

Volumn 310, Issue 1, 2003, Pages 153-157

  Hamada, Yoshinosuke ^a   Nokihara, Kiyoshi ^b   Okazaki, Masayuki ^c   Fujitani, Wataru ^a   Matsumoto, Takuya ^a   Matsuo, Mitsuyoshi ^d   Umakoshi, Yukichi ^a   Takahashi, Junzou ^a   Matsuura, Nariaki ^a  

^a OSAKA UNIVERSITY   (Japan)

^b Hipep Laboratories Inc   (Japan)

^c HIROSHIMA UNIVERSITY   (Japan)

^d KONAN UNIVERSITY   (Japan)

Author keywords

Angiogenesis; Differentiation; Endothelial cells; Osteopontin; SVVYGLR; Tube formation

Indexed keywords

OSTEOPONTIN; PEPTIDE DERIVATIVE; SERYLVALYLVALYLTYROSYLGLYCYLLEUCYLARGININE; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL CELL; ARTICLE; CELL ACTIVITY; CELL ADHESION; CELL DIFFERENTIATION; CELL JUNCTION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG POTENCY; ELECTRON MICROSCOPY; ENDOTHELIUM CELL; MICROVILLUS; MOLECULAR WEIGHT; NONHUMAN; PRIORITY JOURNAL; RAT; TIGHT JUNCTION;

EID: 0141720757     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbrc.2003.09.001     Document Type: Article

References (33)

1. Folkman J., D'Amore P.A. Blood vessel formation: what is its molecular basis? Cell. 87:1996;1153-1155.
2. Risau W. Mechanisms of angiogenesis. Nature. 386:1997;671-674.
3. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other diseases. Nat. Med. 1:1995;27-31.
4. Colville-Nash P.R., Willoughby D.A. Growth factors in angiogenesis: Current interest and therapeutic potential. Mol. Med. Today. 3:1997;14-23.
5. Friesel R.E., Maciag T. Molecular mechanisms of angiogenesis: fibroblast growth factor signal transduction. FASEB J. 9:1995;919-925.
6. Tallquist M.D., Soriano P., Klinghoffer R.A. Growth factor signaling pathways in vascular development. Oncogene. 18:1999;7917-7932.
7. Ferrara N., Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr. Rev. 18:1997;4-25.
8. Shibuya M. Role of VEGF-flt receptor system in normal and tumor angiogenesis. Adv. Cancer Res. 67:1995;281-316.
9. Folkman J., Klagsbrun M. Angiogenic factors. Science. 235:1987;442-447.
10. Mustonen T., Alitalo K. Endothelial receptor tyrosine kinases involved in angiogenesis. J. Cell Biol. 129:1995;895-898.
11. Nakamura Y., Morishita R., Higaki J., Kida I., Aoki M., Moriguchi A., Yamada K., Hayashi S., Yo Y., Nakano H., Matsumoto K., Nakamura T., Ogihara T. Hepatocyte growth factor is a novel member of endothelium-specific growth: additive stimulatory effect of hepatoctye growth factor with basic fibroblast growth factor but not with vascular endothelial growth factor. J. Hypertens. 14:1996;1067-1072.
12. Nakagami H., Morishita R., Yamamoto K., Taniyama Y., Aoki M., Matsumoto K., Nakamura T., Kaneda Y., Horiuchi M., Ogihara T. Mitogenic and antiapoptotic action of hepatocyte growth factor through ERK, STAT3, and AKT in endothelial cells. Hypertension. 37:2001;581-586.
13. Okumura M., Okuda T., Nakamura T., Yajima M. Acceleration of wound healing in diabetic mice by basic fibroblast growth factor. Biol. Pharm. Bull. 19:1996;530-535.
14. Tanaka E., Ase K., Okuda T., Okumura M., Nogimori K. Mechanism of acceleration of wound healing by basic fibroblast growth factor in genetically diabetic mice. Biol. Pharm. Bull. 19:1996;1141-1148.
15. Kovalenko D., Yang X., Nadeau R.J., Harkins L.K., Friesel R. Sef inhibits fibroblast growth factor signaling by inhibiting FGFR1 tyrosine phosphorylation and subsequent ERK activation. J. Biol. Chem. 18:2003;14087-14091.
16. Facchiano A., Russo K., Facchiano A.M., De Marchis F., Facchiano F., Ribatti D., Aguzzi M.S., Capogrossi M.C. Identification of a novel domain of fibroblast growth factor 2 controlling its angiogenic properties. J. Biol. Chem. 278:2003;8751-8760.
17. Delgado M., Ganea D. Vasoactive intestinal peptide inhibits IL-8 production in human monocytes by downregulating nuclear factor kappaB-dependent transcriptional activity. Biochem. Biophys. Res. Commun. 302:2003;275-283.
18. Heidemann J., Ogawa H., Dwinell M.B., Rafiee P., Maaser C., Gockel H.R., Otterson M.F., Ota D.M., Lugering N., Domschke W., Binion D.G. Angiogenic effects of interleukin 8 (CXCL8) in human intestinal microvascular endothelial cells are mediated by CXCR2. J. Biol. Chem. 278:2003;8508-8515.
19. Tsuda S., Ohtsuru A., Yamashita S., Kanetake H., Kanada S. Role of c-Fyn in FGF-2-mediated tube-like structure formation by murine brain capillary endothelial cells. Biochem. Biophys. Res. Commun. 290:2002;1354-1360.
20. Sodek J., Ganss B., Mckee M.D. Osteopontin. Crit. Rev. Oral. Biol. Med. 11:2000;279-303.
21. Liu Y.K., Uemura T., Nemoto A., Yabe T., Fujii N., Ushida T., Tateishi T. Osteopontin involvement in integrin-mediated cell signaling and regulation of expression of alkaline phosphatase during early differentiation of UMR cells. FEBS. Lett. 420:1997;112-116.
22. Nomura S., Wills A.J., Edwards D.R., Heath J.K., Hogan B.L. Developmental expression of 2ar (osteopontin) and SPARC (osteonectin) RNA as revealed by in situ hybridization. J. Cell Biol. 106:1988;441-450.
23. Liu Y.K., Nemoto A., Feng Y., Uemura T. The binding ability to matrix proteins and the inhibitory effects on cell adhesion of synthetic peptides derived from a conserved sequence of integrins. J. Biochem. 121:1997;961-968.
24. Komori T., Yagi H., Nomura S., Yamaguchi A., Sasaki K., Deguchi K., Shimizu Y., Bronson R.T., Gao Y.H., Inada M., Sato M., Okamoto R., Kitamura Y., Yoshiki S., Kishimoto T. Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell. 89:1997;755-764.
25. Shijubo N., Uede T., Kon S., Maeda M., Segawa T., Imada A., Hirasawa M., Abe S. Vascular endothelial growth factor and osteopontin in stage I lung adenocarcinoma. Am. J. Respir. Crit. Care Med. 160:1999;1269-1273.
26. Takano S., Tsuboi K., Tomono Y., Mitsui Y., Nose T. Tissue factor, osteopontin, alphavbeta3 integrin expression in microvasculature of gliomas associated with vascular endothelial growth factor expression. Br. J. Cancer. 82:2000;1967-1973.
27. Prols F., Loser B., Marx M. Differential expression of osteopontin, PC4, and CEC5, a novel mRNA species, during in vitro angiogenesis. Exp. Cell Res. 25(239):1998;1-10.
28. Yokosaki Y., Matsuura N., Sasaki T., Murakami I., Schneider H., Higashiyama S., Saitoh Y., Yamakido M., Taooka Y., Sheppard D. The Integrin. α9β1 bind to a novel recognition sequence (SVVYGLR) in the thrombin-cleaved amino-terminal fragment of osteopontin J. Biol. Chem. 274(51):1999;36328-36334.
29. Jiang B., Morimoto S., Yang J., Niinoabu T., Fukuo K., Ogihara T. Expression of parathyroid hormone/parathyroid hormone-related protein receptor in vascular endothelial cells. J. Cardiovasc. Pharmacol. 31:1998;S142-S144.
30. Ishiyama M., Miyazono Y., Sasamoto K., Ohrkura Y., Ueno K. A highly water-soluble disulfonated tetrazolium salt as a chromogenic indicator for NADH as well as cell viability. Taranta. 44:1997;1299-1305.
31. Main A.L., Harvey T.S., Baron M., Boyd J., Campbell I.D. The three-dimensional structure of the tenth type III module of fibronectin: an insight into RGD-mediated interactions. Cell. 71:1992;671-678.
32. Talks K.L., Harris A.L. Current status of antiangiogenic factors. Br. J. Haematol. 109:2000;477-489.
33. Liu X., Huang M., Peng X., Xiao W., Wang Y. The role of YIGSR and RGD peptides in regulating fenestrae of sinusoidal endothelial cells. Hua Xi Yi Ke Da Xue Xue Bao. 32(338-340):2001;375.